Products for Research Use Only

BMS-687453

CAT: 0804-HY-10678-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10678-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
CAS Number
1000998-59-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/BMS-687453.html
Purity
99.31
Solubility
DMSO : ≥ 100 mg/mL
Smiles
ClC(C=C1)=CC=C1C2=NC(COC3=CC=CC(CN(C(OC)=O)CC(O)=O)=C3)=C(C)O2
Molecular Formula
C22H21ClN2O6
Molecular Weight
444.86
Precautions
H302, H315, H319, H335
References & Citations
[1]Li J, et al. Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2- ((3- ((2- (4-chlorophenyl) -5-methyloxazol-4-yl) methoxy) benzyl) (methoxycarbonyl) amino) acetic acid (BMS-687453) . J Med Chem. 2010 Apr 8;53 (7) :2854-64.|[2]Mukherjee R, et al. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther. 2008 Dec;327 (3) :716-26.|[3]Vassallo JD, et al. Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin. Toxicol Sci. 2009 Oct;111 (2) :402-12.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARα